Wisteria floribunda Agglutinin-Positive Mucin 1 Is a Sensitive Biliary Marker for Human Cholangiocarcinoma

Atsushi Matsuda,1 Atsushi Kuno,1 Toru Kawamoto,2 Hideki Matsuzaki,1 Tatsuro Irimura,3 Yuzuru Ikehara,1 Yoh Zen,4 Yasuni Nakanuma,4 Masakazu Yamamoto,5 Nobuhiro Ohkohchi,6 Junichi Shoda,7 Jun Hirabayashi,1 and Hisashi Narimatsu1

Cholangiocarcinoma (CC) is an aggressive malignant tumor for which useful markers are not presently available for early and precise diagnosis. The aim of this study was therefore to identify a high-performance diagnostic marker with a special focus on glyco-alteration of glycoproteins. In the course of study, we found that Wisteria floribunda agglutinin (WFA) is the best probe to differentiate intrahepatic cholangiocarcinoma (ICC) lesions from normal bile duct epithelia (BDE) ($P < 0.0001$). The subsequent histochemical study confirmed ICC-specific WFA staining on 165 tissue specimens. On the other hand, the WFA staining was shown to be closely associated with that of MY.1E12 established previously against sialylated mucin 1 (MUC1) by double-staining experiments. Moreover, glyco-alteration of MUC1 could be verified by western blotting of WFA-captured bile samples from patients with CC patients. Thus, we attempted to construct an enzyme-linked immunosorbent assay system for more convenient CC diagnosis, where WFA-coated plates, the specific monoclonal antibody MY.1E12, and the bile specimens from CC including ICC ($n = 30$) and benign diseases ($n = 38$) were combined. As a result, CC was clearly distinguished from benign diseases with statistical scores (sensitivity = 90.0%, specificity = 76.3%, and area under the curve = 0.85). As a particular note, the obtained sensitivity is the highest score among those having been so far reported. Conclusion: Our approach focusing significant glyco-alteration of a particular glycoprotein yielded a novel diagnostic system for CC with satisfactory clinical scores. (HEPATOLOGY 2010;52:174-182)

Cholangiocarcinoma (CC) is an aggressive malignant tumor arising from the epithelial lining of the intrahepatic biliary tract. Although it contributes to only 15% of the total incidence of primary liver cancer,1 recent epidemiological reports show that the CC incidence has increased significantly in

**Abbreviations:** AFP, alpha-fetoprotein; AUC, area under the curve; BDE, bile duct epithelia; BSA, bovine serum albumin; CA19-9, carbohydrate antigen 19-9; CC, cholangiocarcinoma; CEA, carcinoembryonic antigen; ELISA, enzyme-linked immunosorbent assay; GalNAc, N-acetylgalactosamine; GlcNAc, N-acetylglucosamine; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma; mAb, monoclonal antibody; MUC1, mucin 1; OD, optical density; PBS, phosphate-buffered saline, pH 7.4; PBS-t, PBS containing 0.1% Tween20; PBSTx, PBS containing 1% Triton X-100; ROC, receiver operating characteristic; TBS, Tris-buffered saline, pH 7.4; TBS-t, TBS containing 0.1% Tween20; TBSTx, TBS containing 1% Triton X-100; WFA, Wisteria floribunda agglutinin.

From the 1Research Center for Medical Glycoscience (RCMG), National Institute of Advanced Industrial Science and Technology (AIST), AIST Tsukuba Central 2, Tsukuba, Ibaraki, Japan; 2Tsukuba Stomach and Intestinal Hospital, Tsukuba, Ibaraki, Japan; 3Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan; 4Department of Human Pathology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan; 5Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan; 6Department of Surgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan; and 7Field of Basic Sports Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Received January 8, 2010; accepted February 26, 2010.

This study was supported in part by a grant from New Energy and Industrial Technology Development Organization (NEDO) in Japan.

Address reprint requests to: Hisashi Narimatsu, Research Center for Medical Glycoscience (RCMG), National Institute of Advanced Industrial Science and Technology (AIST), AIST Tsukuba Central 2, 1-1-1 Umezono, Tsukuba, Ibaraki 305-8568, Japan. E-mail: h.narimatsu@aist.go.jp; fax: +81-29-861-3191.

Copyright © 2010 by the American Association for the Study of Liver Diseases.

Published online in Wiley InterScience (www.interscience.wiley.com).

DOI 10.1002/hep.23654

Potential conflict of interest: Nothing to report.

Additional Supporting Information may be found in the online version of this article.
the past decades. Because of the late clinical presentation, CC is in most cases fatal by the time it becomes clinically evident. From a general viewpoint, prognosis of CC is also poor, with a 5-year survival rate of less than 5%. Therefore, CC can be cured if a surgical resection is performed at a relatively early stage. In clinical practice, however, CC is not easily amenable to surgery because most diagnoses are made at the advanced stage. As a result, 75% of patients with CC die within 1 year of diagnosis.

As conventional serum CC markers, carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) are used widely. However, they are not necessarily good CC markers in terms of sensitivity. CA125 is also described as a potential CC marker in serum, although its sensitivity is much lower (40%-50%). Recently, serum Mac-2-binding protein has been nominated as a new CC marker in serum. Nevertheless, its sensitivity is as low as 68.8%. Moreover, serum concentrations of these markers, e.g., CA19-9, are known to be elevated in other malignant tumors, as well as in benign diseases, such as cholelithiasis or hepatolithiasis associated with cholangitis. In this respect, serum is a difficult target to develop high-specificity diagnosis markers. In this context, CA19-9 and CEA can also be expected to be useful for bile diagnosis. Unfortunately, the sensitivity of CA19-9 is not high enough, and that of CEA is still lower. At present, however, CA19-9 is regarded as a "high-sensitivity" marker for the bile diagnosis of CC, although the reported diagnostic scores are not satisfactory; i.e., 65.0% (sensitivity), 69.0% (specificity), and 0.69 (area under the curve [AUC]). On the other hand, imaging techniques such as ultrasonography, computed tomography, and magnetic resonance cholangiography are also performed as well as pathological diagnosis for confirmation of CC. However, this diagnosis of CC is difficult because of its location, size, and desmoplastic characteristics. Regarding the diagnosis of CC, biliary cytology and brush cytology are performed routinely, although the sensitivity of exfoliative biliary cytology is generally low (40%-69%). Thus, a novel biological diagnostic marker for CC is needed to provide a fully workable method to identify the lesion at as early a stage as possible.

Aberrant glycosylation is often associated with individual steps of carcinogenesis and progression. For example, CA19-9 is a representative carbohydrate antigen, sialyl-Lea, whose expression is associated closely with cancers originating from digestive tissues. Critically, however, core proteins that carry this classic epitope have not been characterized fully. By contrast, α-fetoprotein (AFP) has been shown to function as a good diagnostic marker of hepatocellular carcinoma (HCC), and its sensitivity and specificity have been improved significantly by combining measurement of AFP level with Lens culinaris agglutinin reactivity (AFP-L3). AFP-L3 is defined as a glycoprotein carrying biantennary N-glycan(s) having a α1,6 core fucose, whose expression is relatively low in liver cirrhosis. This difference in expression emphasizes the importance of glycosylation change (glyco-alteration) occurring on the same protein. Thus, glyco-alteration of particular glycoproteins has attracted increasing attention among biomarker investigators.

We recently developed a simple and ultrasensitive procedure for differential glycan profiling based on a lectin microarray. This novel array technology enables a straightforward, high-throughput glycan analysis with multiplex lectins that can target even formalin-embedded small tissue sections (<1.5 mm in diameter, 5 μm in thickness). Using this advanced technology, we identified Wisteria floribunda agglutinin (WFA) as the best probe to detect glyco-alteration in ICC and to distinguish the expression in ICC lesions from that in normal specimens. We further identified mucin 1 (MUC1) as a potential ICC-specific glycoprotein marker that carries WFA-positive glycans. MUC1 is known as a highly glycosylated mucin associated with malignancy in many other organs. Using two relevant probes, i.e., α/β-N-acetylgalactosamine (GalNAc)-specific lectin (WFA) and anti-sialylated MUC1 monoclonal antibody (mAb) (MY.1E12), we developed a novel sandwich (i.e., lectin-antibody) assay system. The established enzyme-linked immunosorbent assay (ELISA) system allows the direct diagnosis using human bile specimens with far better sensitivity (90.0%) than that provided by any of the previous CC diagnosis systems including bile cytology.

Patients and Methods

Specimens. Archival formalin-fixed, paraffin-embedded liver tissue specimens from 105 surgical cases of ICC (14 with hepatolithiasis and 91 without hepatolithiasis), 10 cases of hepatocellular-intrahepatic cholangiocellular carcinoma (HCC-ICC), 25 cases of HCC, and 25 samples of normal liver (from patients with metastatic liver tumors) were used in this study. Supporting Table 1 summarizes the sex and mean age of the patients, and the pathological features of these cases. In detail, tissue specimens from 45 cases of ICC (14 with hepatolithiasis and 31 without) were used in
the lectin microarray analysis. For histochemical analysis, specimens from 83 cases of ICC, 10 cases of HCC-ICC, 25 cases of HCC, and 25 normal livers were used.

Bile specimens were obtained by percutaneous transhepatic biliary drainage from 18 patients with CC and at surgery from 12 patients with CC. In the analysis of bile cytology, three of the 18 specimens obtained by percutaneous transhepatic biliary drainage were positive (class V), eight were negative (class I, II, or IIIa), and the other seven were suspect (class IIIb or IV). These bile samples were obtained from the patients diagnosed with CC by surgical resection. In addition, for 16 patients with hepatolithiasis, ductal bile was obtained at surgery from the hepatic ducts affected by intrahepatic stones and the unaffected hepatic ducts, with particular care taken to avoid contamination with blood. For patients with common bile duct stones (n = 9), gallbladder stones (n = 10), cholangiectasis (n = 1), bile duct stenosis (n = 1), and pancreatitis (n = 1), ductal bile was also obtained from the common bile ducts at surgery. The bile specimens were stored at −80°C until use. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki (1975). All patients provided written informed consent for the analysis of the biopsy specimens or drainage bile. The protocol for this study was approved by the ethical committee of Kanazawa University, Tokyo Women’s Medical University and University of Tsukuba.

**Lectin Microarray Analysis Using Samples from Tissue Sections.** Differential glycan profiling of tissue sections was performed essentially as described. Briefly, formalin-fixed, paraffin-embedded ICC tissue sections were deparaffinized, and the relevant tissue fragments including cancerous (n = 45) and normal bile duct epithelia (BDE) (n = 38) lesions (corresponding to 1.0 mm square and 5 μm thickness, respectively) were then scratched from the glass slide using a needle (gauge size: 21 G) under a microscope. Total protein extracts from the scratched tissue fragments thus obtained were fluorescence-labeled with 10 μg of Cy3-succimidyl ester (SE; Amersham Biosciences, Tokyo, Japan). After blocking free Cy3-SE with 0.5 M glycin in Tris-buffered saline containing 1% Triton X-100 (TBSTx), an aliquot (1/4) was applied to a lectin microarray slide. Fluorescence signals were measured on a GlycoStation scanner (Moritex Co., Tokyo, Japan). The obtained lectin microarray data were analyzed on the basis of normalized signal intensities as described, where the lectin showing the strongest signal intensity (max intensity) was assigned a value of 1.0.

**Statistics.** The values are presented as the median ± standard error of the mean (SEM). A two-sided Welch or Student t test was used to compare the clinicopathological data between groups. All calculations were performed using Origin version 7.5 software for Windows (OriginLab Co., Northampton, MA). Receiver operating characteristic (ROC) curve analysis was performed to evaluate the differences between ICC and benign disease on the bases of sensitivity and specificity at various cutoff levels. An area under the ROC curve (AUC) of 1.0 indicates perfect discrimination, whereas an area of 0.5 indicates that the test discriminates no better than chance.

**Histochemical Analysis.** WFA staining was performed using biotinylated WFA (Vector Co., Burlingame, UK). Detection was made with Histofine Simple Stain MAX-PO (Nichirei Co., Tokyo, Japan). The tissue sections were deparaffinized and then autoclaved to enhance the WFA reactivity. After cooling to room temperature, endogenous peroxidase was blocked by incubating the sections in methanol containing 0.3% hydrogen peroxide. The tissue sections were blocked with phosphate-buffered saline (PBS) containing 1% (wt/vol) bovine serum albumin (BSA), and the sections were incubated with 2 μg/mL of biotinylated WFA in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid for 1 hour at room temperature. The sections were incubated with streptavidin–peroxidase reagents, reacted with 3,3′-diaminobenzidine tetrahydrochloride for visualization, and counterstained with hematoxylin.

Fluorescent double-staining was performed with biotinylated WFA and Cy5-SE–labeled anti-biotin antibody, together with mAb MY.1E12, whose epitope structure has been established, MUC1 with sialylated-T antigen, and Alexa Fluor 488–labeled secondary antibody. For nucleic acid staining, the slides were incubated with TO-PRO-3 (Invitrogen, Carlsbad, CA; 1:5000 in PBS) for 10 minutes. The slides were washed with PBS, mounted in ProLong Gold Antifade Reagent (Invitrogen) and examined using an LSM 510 confocal laser microscope (Carl Zeiss Inc., Oberkothen, Germany).

**Lectin-Affinity Purification of Bile Specimens.** Bile samples from the patients with central type CC and the patients with hepatolithiasis were centrifuged at 16,000g for 20 minutes at 4°C, and the supernatants were collected. The protein concentration was measured with Micro BCA (Pierce, Rockford, IL) using BSA as a standard. For WFA-affinity purification, 20 μg of total protein from the bile samples described above and 2 μg of preconjugated biotinylated WFA, streptavidin-immobilized magnetic beads (Streptavidin-coupled Dynabeads; Invitrogen) were used. The beads were incubated with bile for 9 hours at 4°C, the supernatants were then excluded, and the beads were...
washed twice with 200 μL of PBS containing 1% Triton X-100 (PBSX). Elution was performed with 10 μL of elution buffer (1% sodium dodecyl sulfate in PBS containing 0.2 M galactosamine). To ensure complete elution, the beads were incubated overnight at room temperature, and the supernatants were then collected and used as the eluted fractions.

**Western Blotting Analysis Using MY.1E12 mAb.** The eluted fractions and 20 μg of supernatants in the crude bile samples were dissolved in sample buffer (12 mM Tris-HCl, pH 6.8, 5% [vol/vol] glycerol, 0.4% sodium dodecyl sulfate, 0.02% bromophenol blue). The proteins were separated by 1% agarose gel electrophoresis at 50 mA for 90 minutes under nonreducing conditions and then transferred onto a polyvinylidene fluoride membrane by vacuum blotting. The transferred membrane was blocked with 4% (wt/vol) skim milk in TBS-t (TBS containing 1% Tween 20) overnight at 4°C and then incubated with 0.5 μg/mL of mAb MY.1E12 in TBS-t containing 1% BSA for 2 hours at room temperature. After washing with TBS-t, the membrane was incubated with 1/10,000-diluted alkaline phosphatase-conjugated anti-mouse IgG in TBS-t for 1 hour at room temperature. After washing, the membrane was visualized with Western blue detection reagents (Promega, Madison, WI).

**Sandwich ELISA with Combination of MY.1E12 and WFA.** Flat-bottomed 96-well streptavidin-pre-coated microtiter plates (Nunc International, Tokyo, Japan) were treated with biotinylated WFA (Vector, 1.0 μg/well) for immobilization for 1 hour at room temperature. The plates were incubated with bile (protein amount adjusted to 10 μg/well) in PBS containing 0.1% Tween20 (PBS-t) for 2 hours at room temperature and then with either 50 ng/well of MY.1E12 in PBS-t for 2 hours at room temperature. For conventional antibody-antibody sandwich assay as a control, MY.1E12 (0.5 μg/well) was coated on flat-bottomed 96-well microtiter plates (Greiner Bio-one Co., Tokyo, Japan), and 100 ng/well of biotinylated MY.1E12 in PBS-t was overlaid. The plates were washed extensively and then incubated with 100 μL of either a 1/4000-diluted solution of horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Jackson ImmunoResearch Laboratories Inc., Philadelphia, PA) in PBS-t for MY.1E12 or a 1/20,000 diluted solution of HRP-conjugated streptavidin (Jackson) in PBS-t for biotinylated MY.1E12 for 1 hour at room temperature. One hundred microliters of the substrate 3,3′,5,5′-tetramethyl benzidine (Thermo Fisher Scientific, Fremont, CA) solution was added to each well. The enzyme reaction was stopped by adding 100 μL of 1 M sulfuric acid, and the optical density (OD) was measured at 450 nm. For differential analysis, the ratios were measured relative to values in healthy volunteer sera. All experiments were performed in duplicate, and the median was used as the final value for each sample.

**Results**

**Lectin-Microarray Analysis Using Tissue Sections.** To identify the most relevant lectin specific for CC, we first performed differential glycan profiling using paraffin-embedded, formalin-fixed ICC tissue sections, which include both cancerous lesions and normal BDE (Supporting Table 2). We found significant differences in several lectins. The signal intensities of four lectins, T/Tn-antigen binder BPL, H-antigen binder TJA-II, terminal αβ-GalNAc binder WFA, and a T-antigen binder ACA, were higher in the cancerous lesions than in the normal BDE. The ratios between the values in tumor versus normal BDE (T/N) for the relative signals were 2.3 for BPL, 2.4 for TJA-II, 4.6 for WFA, and 2.0 for ACA, respectively. These were significant at \( P < 0.0001 \). Comparison of cancerous lesions and normal BDE in the same patient’s specimen (14 and 10 cases with and without stones, respectively) showed the highest values for the WFA signal among the four lectins (\( P < 0.0001 \) without stones and \( P < 0.0015 \) with stones) (Fig. 1). The WFA signal also showed the best result in the ROC curve analysis, with high scores for sensitivity (87.4%), specificity (92.1%), and AUC (0.93) (Table 1). These results strongly suggest that the high WFA signal observed correlated closely with the glycosylation change specific for cancerous lesions of ICC.

**Histochemical Approach to Analyze the Specific Expression of WFA-Reactive Glycans in ICC.** To confirm the above result, we took a histochemical approach to visualize the expression of WFA-reactive glycans using biotinylated WFA. Cancerous lesions of ICC (n = 90), normal BDE (n = 25), hepatocellular carcinoma (HCC) (n = 25), and combined HCC-ICC (n = 10) were used as specimens. The observed results are summarized in Table 2. In the ICC cancerous lesions, significant WFA staining was detected with high frequency in both ICC (83/90; 92.2%) and ICC elements of HCC-ICC (8/10; 80.0%). In normal BDE, some staining was observed, but with much less frequency (8/25; 32.0%) and intensity than for the cancerous lesions (Fig. 2). Conversely, no WFA-positive staining was observed (0/10; 0%) in hepatocellular carcinoma cells of HCC and HCC lesions of HCC-
ICC. These results support the idea that WFA-reactive glycans are expressed specifically in ICC.

**Double-Staining Analysis with MY.1E12 and WFA.** It is known that the expression of sialylated MUC1 increases in CC and correlates significantly with tumor malignancy. For this molecular species, a specific mAb, MY.1E12, has been established and characterized.25,26,31,32 We investigated the possibility that sialylated MUC1 colocalizes with the WFA-reactive glycans using a fluorescence double-staining method of ICC tissue sections. The staining was performed with MY.1E12 and Alexa Fluor 488-labeled anti-mouse IgG antibody (green, Fig. 3B), together with biotinylated WFA and Cy5-SE–labeled anti-biotin mAb (red, Fig. 3C). Both WFA and MY.1E12 probes stained mainly the apical surface of epithelial cells in the cancerous lesions (Fig. 3B,C). The two stains merged well (yellow, Fig. 3D). These results indicated that WFA-reactive glycans are carried, at least partly, on sialylated MUC1 in cancerous lesions.

**Pulldown Assay of Sialylated MUC1- and WFA-Reactive Glycoproteins in Bile.** The above results strongly implied that sialylated MUC1 is a candidate glycoprotein that carries ICC-associated, WFA-reactive glycans. As the next step, we performed a pulldown assay using biotinylated WFA preconjugated streptavidin beads and bile samples. The samples were the bile specimens from hepatolithiasis patients as the benign disease control (n = 5) and from patients of intra and extra hepatic CC (n = 5). The pretreated bile was probed with MY.1E12 by western blotting (for experimental details, see Patients and Methods). The presence of sialylated MUC1 was observed even in the

---

**Table 1. ROC Curve Analysis of the Data Obtained in the Lectin Microarray**

|                | BPL | TJA-II | WFA | ACA |
|----------------|-----|--------|-----|-----|
| Normal BDE (n = 38) |     |        |     |     |
| Positive        | 4   | 6      | 3   | 8   |
| Negative        | 34  | 32     | 35  | 30  |
| ICC (n = 45)    |     |        |     |     |
| Positive        | 28  | 32     | 39  | 30  |
| Negative        | 17  | 13     | 6   | 15  |
| Specificity (%) | 89.5| 84.2   | 92.1| 79.0|
| Sensitivity (%) | 62.2| 71.1   | 87.4| 66.7|
| AUC            | 0.80| 0.83   | 0.93| 0.78|

Abbreviations: AUC, area under the curve; BDE, bile duct epithelia; ICC, intrahepatic cholangiocarcinoma.

**Table 2. Summary of Histochemical Analysis with WFA**

| Tissue Specimens          | WFA Stain |
|---------------------------|-----------|
|                            | Negative  | Positive |
| ICC (n = 90)              | 7 (8%)    | 83 (92%) |
| Combined HCC-ICC (n = 10) | 2 (20%)   | 8 (80%)  |
| ICC                       | 10 (100%) | 0 (0%)   |
| HCC                       | 25 (100%) | 0 (0%)   |
| Normal BDE (n = 25)       | 17 (68%)  | 8 (32%)  |

Abbreviations: BDE, bile duct epithelia; HCC-ICC, combined hepatocellular cholangiocarcinoma; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma.
crude bile in four of five control samples, and all five CC samples (Fig. 4A), indicating that sialylated MUC1 is a common structure to both hepatolithiasis and CC. By contrast, sialylated MUC1 expression was much lower in WFA-pretreated bile (only one of five samples) but was observed in all five CC samples (Fig. 4B). These results show clearly that sialylated MUC1 carries WFA-reactive glycans contained in the bile of CC patients.

**Diagnosis of Bile-Sialylated MUC1 with mAb MY.1E12/WFA Sandwich ELISA.** Because the WFA-MY.1E12 combination showed good potential to identify CC-specific markers in bile (Fig. 4), we next attempted to develop a sandwich ELISA system, where WFA is immobilized to capture CC-specific glycan moiety and MY.1E12 is used as the detection probe (for experimental details, see Patients and Methods). The assay was performed to distinguish CC (n = 30, comprising intra and extra hepatic CC) from benign duct disease bile with hepatolithiasis (n = 16), common bile duct stones (n = 9), gallbladder stones (n = 10), cholangiectomy (n = 1), bile duct stenosis (n = 1), and autoimmune pancreatitis (n = 1). S/N ratios were determined with normal sera of healthy volunteers as a negative control (n = 3). The values were significantly higher in patients with CC than in those with benign bile duct disease (P = 0.0004; Fig. 5A). To evaluate the performance of the ELISA system in discriminating CC from benign bile duct diseases, we analyzed the ROC curve. The AUC = 0.86 at a cutoff value of S/N = 6.64 (solid line in Fig. 5C), providing the best separation (i.e., minimal false-negative and
false-positive results). We correctly identified 27 of 30 patients with CC (90.0% sensitivity) and excluded 29 of 38 patients with benign duct disease (76.3% specificity). For comparison, a conventional format of antibody-antibody sandwich system, i.e., MY.1E12-MY.1E12, was also performed. However, none of the obtained scores was better than those of the present WFA-MY.1E12 system: \( P = 0.0138 \). The sensitivity was 56.7%; specificity, 84.2%; and AUC, 0.75 at a cutoff value of S/N = 9.36 (Fig. 5B and broken line in Fig. 5C). These results are better than those produced by biliary cytology (Table 3).

**Discussion**

Early and correct diagnosis of CC is still an urgent issue even with the aid of modern detection technologies. Although many CC-associated serological markers, such as CA19-9, MUC5AC, and Mac-2-binding protein, have been proposed, none of them has satisfactory sensitivity. With special focus on cancer-associated glyco-alteration, we recently proposed a robust strategy to develop high performance glycoprotein biomarkers using advanced technologies of glycoproteomics. Along with the established strategy, we attempted differential glycan analysis using tissue sections containing both normal BDE and ICC lesions from the same patients. An ultrasensitive glycan profiling technology, lectin microarray mined WFA as the most promising probe to differentiate ICC from normal BDE with a significant \( P \) value (<0.0001). Subsequent histochemical analysis of 150 ICC sections using biotinylated WFA could confirm the strong expression of WFA-reactive glycans specific in cancerous lesions.

The main aim of this study is to develop a robust diagnostic system targeting molecular bio-markers involved in body fluids. We have chosen bile as the primary target, because the bile is in direct downstream of CC, and thus, is expected to contain much higher amounts of candidate marker molecules than in serum. In this study, we hypothesized that sialylated MUC1, established as an antigen for MY.1E12 monoclonal antibody and known to express well in BDE and CC cells, is one of the glycoproteins that carries the WFA-reactive glycans. As expected, staining with both MY.1E12 and WFA merged well in the cancerous lesions in ICC tissue sections (Fig. 3). In addition, the presence of sialylated MUC1 carrying WFA-reactive glycans was confirmed by western blot analysis using WFA-enriched bile fractions (Fig. 4). Therefore, it is conclusive that sialylated MUC1 is a carrier protein of WFA-reactive glycans in both ICC tissues and bile fluids. Thus, we developed a novel sandwich ELISA system that combined WFA and MY.1E12 to target bile samples (30 cases of CC and 38 cases of benign bile duct diseases). The sensitivity (90.0%) and AUC (0.86) obtained were superior to those produced by previous methods. Biliary cytology gave only poor sensitivity (10/18; 55.6%), though it is performed as a routine test in the present diagnosis of biliary tract carcinoma. The result of CA19-9 using a commercial kit and the same specimens for comparison was also unsatisfactory: i.e., sensitivity (62.1%), specificity (51.4%), and AUC (0.56) (Matsuda et al., detailed data unpublished). On the other hand, the obtained specificity of the present assay was relatively low (76.3%). However, there remains possibility that nine cases of the “false positive” among the present group of benign duct diseases (gallbladder stone, common bile duct stone and hepatolithiasis) included “premalignancy” with serious inflammation. In fact, our preliminary histochemical experiments detected
coincidental expression of WFA-reactive glycans and sialylated MUC1 in premalignant conditions (data not shown). For this validation, further evaluation of bile samples from patients with other types of benign diseases, such as primary sclerosing cholangitis and primary biliary cirrhosis, is needed.

Another important result obtained in this study is that WFA staining could also distinguish ICC from HCC elements in the combined type of HCC-ICC (100% accuracy as far as 10 specimens were examined). If WFA staining works so perfectly for ICC-HCC discrimination, it should be of great clinical value, because this task is quite difficult in conventional pathology. Moreover, the combined type of HCC-ICC is mostly fatal, and the cure for ICC differs substantially from that for HCC; whereas radiotherapy is effective for HCC, ICC is resistant.\textsuperscript{35,36} Therefore, the only effective cure for ICC is presently surgical resection at an early stage. For this purpose, several markers or diagnostic systems have been reported. Both cytokeratin families and epithelial cell adhesion molecule (EpCAM) expressed in the BDE and ICC can be used to distinguish ICC from HCC immunohistochemically.\textsuperscript{37-40} Quantitative real-time polymerase chain reaction using several genes can also distinguish ICC from HCC.\textsuperscript{41} Although these approaches target multiple proteins or genes, the proposed WFA-staining approach is simple and sensitive, and combination with the former methods is also possible. Analyzing the expression of WFA-reactive glycans together with these known markers should produce more accurate and convenient methods for diagnosis. To evaluate the usefulness of the WFA-staining method, increase in the number of combined type HCC-ICC specimens is inevitable.

In summary, we demonstrated that our newly developed WFA-MY.1E12 sandwich detection ELISA is a high-sensitivity diagnostic method for CC using bile specimens. Because our new method has much higher sensitivity than biliary cytology, its inclusion in the routine testing for CC in biliary diagnosis is promising. A further validation study with a much larger cohort is the most necessary step to establishing the usefulness of testing for this glycoprotein marker.

Structural analysis of glycans of WFA-associated MUC1 remains to be carried out in a more rigorous manner. This should give useful clues to design a more specific probe (i.e., antibody) than the WFA lectin used in this study. In this respect, our ultimate goal is to develop a robust diagnostic system directly applicable to serum.

**Acknowledgment:** We thank N. Uchiyama, Y. Kubo, J. Murakami, S. Unno, and T. Nakagawa for technical support.

**Table 3. Comparison Between WFA-MY.1E12 and Biliary Cytology**

| Cytology Class | n | Diagnosis/Cytology | Diagnosis/WFA-MY.1E12 |
|---------------|---|--------------------|-----------------------|
| IIIa          | 8 | Negative           | 6/8 (75%)             |
| IIIb-IV       | 6 | Suspect            | 5/6 (83%)             |
| V             | 4 | Positive           | 4/4 (100%)            |

Eighteen bile specimens were analyzed by both WFA-MY.1E12 and biliary cytology. Biliary cytology was diagnosed as positive class V and negative class I, II, or IIIa. Classes IIIb and IV were diagnosed as suspect. In WFA-MY.1E12, the diagnosis was made using the cutoff value obtained (7.59) in the ROC curve analysis (Fig. 5).
assistance. We also thank Y. Itakura and M. Solge for helpful discussion.

References

1. Okuda K, Nakamura Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: pathology and etiology. J Gastroenterol Hepatol 2002; 17:1049-1055.
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353-1357.
3. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001;48:816-820.
4. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-1314.
5. Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Cholangiocarcinoma. Crit Rev Oncol Hematol 2009;69:259-279.
6. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Ribson SD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51:VI1-VI9.
7. Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schullik R, et al. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004;101:1609-1615.
8. Chen C, Shiech SC, Tsao HC, Lin XZ. The assessment of biliary CA125, CA 19-9 and CEA in diagnosing cholangiocarcinoma—the influence of sampling time and hepatolithiasis. Hepatogastroenterology 2002;49:616-620.
9. Ker C, Chen JS, Lee KT, Sheen PC, Wu CC. Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma. J Gastroenterol Hepatol 1991;6:505-508.
10. Saito JC, Joly-Pharaboz MO, Pernas P, Hensley L, Ponchon T, Madjar JJ. Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: a study in 65 patients with bile duct strictures. Hepatology 1998;12:747-752.
11. Kurzawinski T, Deery A, Dooley J, Dick R, Hobbs K, Davidson B. A prospective controlled study comparing brush and bile exfoliative cytology for diagnosing bile duct strictures. Gut 1992;33:1675-1677.
12. Kurzawinski TR, Deery A, Dooley JS, Dick R, Hobbs KE, Davidson BR. A prospective study of biliary cytology in 100 patients with bile duct strictures. Hepatology 1993;18:1399-1403.
13. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A 2002;99:10231-10233.
14. Fukuda M. Possible roles of tumor-associated carbohydrate antigens. Cancer Res 1996;56:2237-2244.
15. Taketa K, Sekiya C, Namiki M, Akamatsu K, Ohya Y, Endo Y, et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1999;107:508-518.
16. Nakagawa T, Miyashi E, Yakushijin T, Hiramatsu N, Igura T, Hayashi N, et al. Glycamic analysis of alpha-fetoprotein L3 in hepatoma cell lines and hepatocellular carcinoma patients. J Proteome Res 2008;7:2222-2233.
17. Ito H, Kuno A, Sawaki H, Sogabe M, Ozaki H, Tanaka Y, et al. Strategy for glycoproteomics: identification of glyco-alteration using multiple glycan profiling tools. J Proteome Res 2009;8:1358-1367.
18. Hirabayashi J. Concept, strategy and realization of lectin-based glycan profiling. J Biochem 2008;144:139-147.
19. Kuno A, Uchiyama N, Kuno-Koseki S, Ebe Y, Takashima S, Yamada M, et al. Evansen-field fluorescence-assisted lectin microarray: a new strategy for glycan profiling. Nat Methods 2005;2:851-858.
20. Uchiyama N, Kuno A, Tateno H, Kubo Y, Mizuno M, Noguchi M, et al. Optimization of evanescent-field fluorescence-assisted lectin microarray for high-sensitivity detection of monoclonal oligosaccharides and glycoproteins. Proteomics 2008;8:3042-3050.
21. Matsuda A, Kuno A, Ishida Y, Kawamoto T, Shoda J, Hirabayashi J. Development of an all-in-one technology for glycan profiling targeting formalin-embedded tissue sections. Biochem Biophys Res Commun 2008;370:259-263.
22. Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta 1999;1473:67-95.
23. Kuno A, Itakura Y, Toyoda M, Takahashi Y, Yamada M, Umezawa A, et al. Development of a data-mining system for differential profiling of cell glycoproteins based on lectin microarray. J Proteomics Bioinform 2008;1:601-607.
24. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-577.
25. Yamamoto M, Bhavanandan VP, Nakamori S, Irimura T. A novel monoclonal antibody specific for sialylated MUC1 mucin. Jpn J Cancer Res 1996;87:488-496.
26. Takeuchi H, Kato K, Denda-Nagai K, Hanisch FG, Clausen H, Irimura T. The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat. J Immunol Methods 2002;270:199-209.
27. Nakagawa T, Uozumi N, Nakano M, Mizuno-Horikawa Y, Okuyama N, Taguchi T, et al. Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem 2006;281:29797-29806.
28. Yamaizaka T, Powers SP, LaRusso NF. Biliary proteins: assessment of quantitative techniques and comparison in gallstone and nongallstone subjects. J Lipid Res 1988;29:1055-1063.
29. Kuno A, Kato Y, Matsuda A, Kato-Kaneko M, Ito H, Amano K, et al. Focused differential glycan analysis with the platform antibody-assisted lectin profiling (ALP) for glycan-related biomarker verification. Mol Cell Proteomics 2009;8:99-108.
30. Ikemura Y, Sato T, Niwa T, Nakamura S, Gotoh M, Ikemura SK, et al. Apical Golgi localization of N,N2-diacetylatedoidamine synthase, βGalNAc-T3, is responsible for LecdiNAc expression on gastric mucosa. Glyobiology 2006;16:777-785.
31. Kawasaki T, Shoda J, Miyaehara N, Suzuki H, Furukawa M, Todoroki T, et al. Expression of MUC1 mucins in the subserosal layer correlates with post-surgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Clin Cancer Res 2001;7:1333-1342.
32. Higashi M, Yonezawa S, Ho JJ, Tanaka S, Irimura T, Kim YS, et al. Expression of MUC1 and MUC2 mucin antigens in inappropriete bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 1999;30:1347-1355.
33. Bamrungphong W, Prempracha N, Bunche N, Rungdaeng S, Sandhu T, Srisukho S, et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUCSAC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett 2007;247:301-308.
34. Narimatsu H, Sawaki H, Kuno A, Kaji H, Ito H, Ikehara Y. A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J 2010;277:99-105.
35. Matsuzaki Y, Osuga T, Saiyo Y, Chuangani Y, Tanaka N, Shoda J, et al. A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma. Gastroenterology 1994;106:1032-1041.
36. Chiba T, Tokuyue K, Matsuzaki Y, Sugahara S, Chuangani Y, Kagei K, et al. Proton beam therapy for hepatocellular carcinoma: A retrospective review of 162 patients. Clin Cancer Res 2005;11:3799-3804.
37. Maeda T, Adachi E, Kajiyama K, Sugimachi S, Tsuneyoshi M. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analyses of clinicopathologic features. Hepatol Res 1995;26:956-964.
38. Johnson DE, Herndier BG, Medeiros LJ, Warnke RA, Rouse RV. The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma. Am J Surg Pathol 1988;12:187-197.
39. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68:1451-1461.
40. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009;136:1012-1024.